FY2029 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Invivyd in a research report issued to clients and investors on Tuesday, February 4th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.41 for the year. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share.

A number of other equities analysts have also issued reports on the company. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research note on Monday. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley cut their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Stock Up 17.9 %

NASDAQ IVVD opened at $1.25 on Wednesday. Invivyd has a 12-month low of $0.35 and a 12-month high of $5.10. The company has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.82.

Insider Activity at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares of the company’s stock, valued at $2,768,228.19. This represents a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by corporate insiders.

Institutional Trading of Invivyd

Institutional investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares during the last quarter. Barclays PLC boosted its stake in shares of Invivyd by 179.6% in the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Invivyd in the 2nd quarter valued at $421,000. Finally, Marshall Wace LLP lifted its holdings in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.